ARS Pharmaceuticals (SPRY) Q1 2025 earnings summary

Executive summary

• neffy, a needle-free intranasal epinephrine, is FDA and EC approved, launched in the US in September 2024, with a 1 mg pediatric dose approved in March 2025 and launched in May 2025, generating $7.8M in U.S. net product revenue in Q1 2025 and strong early adoption among pediatricians and allergists.

• Expanded commercial insurance coverage for neffy from 27% to 57% during Q1 2025, with United Healthcare added and a goal of reaching over 80% by early Q3.

• Entered a co-promotion agreement with ALK-Abelló, expanding direct promotional reach to over 20,000 healthcare providers, including 9,000 pediatricians, and launched a national DTC campaign to drive awareness and adoption.

• ARS targets a $3B+ US epinephrine market, with additional global opportunities through partnerships and regulatory filings in major markets.

• Maintains a strong cash position, expecting current resources to fund operations for at least three years.

Financial highlights

• Q1 2025 revenue was $8.0M, including $7.8M net product sales and $0.2M from ALK collaboration; no revenue in Q1 2024.

• Cost of goods sold was $1.1M, benefiting from pre-approval expensed inventory.

• R&D expenses were $3.0M; SG&A expenses were $41.1M, mainly due to commercialization efforts.

• Net loss for Q1 was $33.9M, or $0.35 per share.

• Cash, cash equivalents, and short-term investments totaled $275.7M as of March 31, 2025.

Outlook and guidance

• Financial position expected to support operations for at least the next three years.

• Expect continued revenue ramp as commercial efforts accelerate and insurance coverage expands, with a sales inflection point anticipated in Q3 2025.

• Project total 2025 operating expenses of $210–$220M (excluding stock-based compensation and COGS), with $40–$50M allocated to DTC marketing in Q2 and Q3.

• Regulatory decisions for neffy anticipated in the UK, Germany (mid-2025), Canada, Australia (year-end 2025), Japan (H2 2025), and China (H1 2026).

• Phase 2b trial for intranasal epinephrine in chronic spontaneous urticaria to begin Q2 2025, with topline data expected in early 2026.